Immunome Announces Pricing of Public Offering of Common Stock
Immunome, Inc. (IMNM)
Company Research
Source: Business Wire
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 18,625,000 shares of its common stock at a price to the public of $21.50 per share. All of the shares are to be sold by Immunome.The gross proceeds to Immunome from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $400 million. In addition, Immunome has granted the underwriters a 30-day option to purchase up to an additional 2,793,750 shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on December 18, 2025, subject to the satisfaction of customary closing conditions.Leerink Partners, J.P. Morgan, TD Cowen, Goldman Sachs & Co. LLC and Guggenheim Securities are acting as joi
Show less
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Immunome Announces Pricing of Public Offering of Common Stock [Yahoo! Finance]Yahoo! Finance
- Immunome (NASDAQ:IMNM) had its "buy" rating reaffirmed by analysts at Lake Street Capital.MarketBeat
- Immunome (NASDAQ:IMNM) had its price target raised by analysts at Evercore ISI from $18.00 to $40.00. They now have an "outperform" rating on the stock.MarketBeat
- Immunome (NASDAQ:IMNM) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Immunome (IMNM) Valuation After Breakthrough Phase 3 RINGSIDE Results and Planned FDA New Drug Application [Yahoo! Finance]Yahoo! Finance
IMNM
Earnings
- 8/6/25 - Beat
IMNM
Sec Filings
- 12/15/25 - Form 424B5
- 12/15/25 - Form 8-K
- 11/7/25 - Form SCHEDULE
- IMNM's page on the SEC website